Japan OKs Listing of Trelegy, Erleada, and More; GSK’s COPD Hopeful to Face Cost-Effectiveness Analysis

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, on May 15 approved a batch of new drugs for their NHI price listing on May 22, including GlaxoSmithKline’s inhaler COPD treatment Trelegy Ellipta...read more